Indian Journal of PsychiatryIndian Journal of Psychiatry
Home | About us | Current Issue | Archives | Ahead of Print | Submission | Instructions | Subscribe | Advertise | Contact | Login 
    Users online: 3195 Small font sizeDefault font sizeIncrease font size Print this article Email this article Bookmark this page
Search Again
 Table of Contents
 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Article Access Statistics
 Reader Comments
 Email Alert
 Add to My List
 * Requires registration (Free)

 Article Access Statistics
    PDF Downloaded307    
    Comments [Add]    
    Cited by others 1    

Recommend this journal

Year : 2006  |  Volume : 48  |  Issue : 1  |  Page : 43-46

A preliminary open trial of olanzapine in paediatric acute and transient psychotic disorders

Department of Psychiatry, King George’s Medical University, Lucknow 226003, Uttar Pradesh, India

Correspondence Address:
Vivek Agarwal
B-1-10/69, Sector K, Aliganj, Lucknow 226024, Uttar Pradesh
Login to access the Email id

Source of Support: None, Conflict of Interest: None

DOI: 10.4103/0019-5545.31618

Rights and Permissions

Background: Acute and transient psychotic disorders (ATPD) have been characterized by the development of florid psychotic symptoms within 2 weeks and complete remission of symptoms. Although there are no definite guidelines, these are usually treated by antipsychotic medication. Aim: This preliminary study examined the effectiveness of olanzapine in paediatric ATPD. Methods: In this 6-week open trial of olanzapine in paediatric ATPD, the patients were rated weekly on the Brief Psychiatric Rating Scale (BPRS), Clinical Global Impression (CGI) Scale and Dosage Record Treatment Emergent Symptom Scale (DOTES). Results: Twenty-three patients (11 males, 12 females; mean age 14.0±1.3 years; range 11-16 years) were included in the study. The mean olanzapine dosage was 12.7±3.9 mg/day (range 5-20 mg/day). All the patients showed significant improvement in 6 weeks. The results showed a significant decrease (p<0.0001) in scores of BPRS (mean at baseline 46.2±7.0 to 21.4±3.9 at week 6). Severity of illness (CGI) decreased from 4.7±0.8 to 1.6±0.9 in 6 weeks. Also, global improvement (CGI) showed marked improvement in 14 (60.9%), good improvement in 8 (34.8%) and minimal improvement in 1 (4.3%) patient. Some common side-effects were dryness of mouth (n=14, 60.9%), increase in appetite (n=12, 52%), weight gain (n=12, 52%) and drowsiness (n=8, 34.8%). No patient developed extrapyramidal symptoms. Conclusion: Olanzapine was safe and effective in paediatric ATPD.



Print this article         Email this article